WVP
DRMAW icon

Worth Venture Partners’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Worth Venture Partners’s Portfolio DRMAW Stock Details DRMAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-40,075
Closed -$17K – 153
2021
Q4 		$17K Hold
40,075
– – 0.01% 118
2021
Q3 		$33K Buy
+40,075
New +$41.2K 0.01% 111

Other funds holding DRMAW

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Worth Venture Partners's DRMAW Position: Q1 2022 in Review

Worth Venture Partners sold out of Dermata Therapeutics Warrant (DRMAW) in Q1 2022, closing a stake of 40,075 shares — an estimated $17K sold.

Worth Venture Partners first reported a position in DRMAW in Q3 2021 and held it in 2 quarters. The position peaked at $33K in Q3 2021. 6 funds tracked by Wall St. Rank hold DRMAW as of Q1 2022.

  • Worth Venture Partners reported no remaining Dermata Therapeutics Warrant position as of Q1 2022 after selling out during the quarter.
  • Worth Venture Partners sold 40,075 Dermata Therapeutics Warrant shares in Q1 2022, an estimated $17K.
  • Worth Venture Partners first reported a position in Dermata Therapeutics Warrant in Q3 2021 and held it in 2 quarters.
  • Worth Venture Partners's Dermata Therapeutics Warrant position peaked at $33K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q1 2022.

Based on Worth Venture Partners's 13F filing for Q1 2022, filed 16 May 2022.